

From: [Weidner, Tara](#)
To: [Kenny Ames](#)
Subject: Additional questions for Papastavros amendment
Date: Wednesday, May 02, 2018 1:36:00 PM

License No.: 07-16529-01

Docket No.: 03030518

Control No.: 602511

PLEASE SEND ME A RETURN E-MAIL TO CONFIRM RECEIPT OF THEIS E-MAIL

Kenny,

Here are the items that I will need addressed. Please respond in a letter signed by the Radnet, dba Delaware Imaging Network management no later than May 11, 2018.

1. Confirm that the name change to Delaware Imaging Network does not constitute a change of control. The change of control took place in 2008 when Radnet acquired Papastavros' Associates.
2. Request that the Delaware Imaging Network license be amended to add the location of use at 12 Omega Drive, Building L, Newark, Delaware and that the amendment should be concurrent with the termination of Omega Nuclear Diagnostics license (07-28190-01).
3. Provide an organizational chart that shows the relationship between Radnet, Delaware Imaging Partners, Inc., the Delaware Imaging Network, and Papastavros Associates Medical Imaging (07-16529-01).
4. Confirm that Delaware Imaging Network will have 2 locations of use: 12 Omega Drive, Building L, Newark, Delaware (formerly Omega Nuclear Diagnostics) and 1701 Augustine Cut-Off, Suite 100, Wilmington, Delaware (formerly Papastavros Associates Medical Imaging).
5. Confirm if any of the following authorized users/uses from Omega Nuclear Diagnostics should be listed on the Delaware Imaging Network license:

Robert L. MeckelInberg, M.D.	35.100; 35.200; 35.300
Myung-Soo Lee, M.D.	35.100; 35.200
Joseph R. Peacock, M.D.	35.100; 35.200

6. On a detailed version of your facility diagram, please indicate the position of each of the areas described below. Section 8.16 of NUREG 1556, Volume 9, Revision 2 may be helpful in preparing your response and provides an example of a facility diagram (Attachment 9.1) that is acceptable to the NRC.
 - a. Storage (refrigerated and nonrefrigerated), preparation and use of radiopharmaceuticals (e.g., lead glass L-block, etc.).
 - b. Storage of radioactive waste, including decay-in-storage prior to disposal as nonradioactive waste. If this area is not located within your main department, describe how you will secure the material.

In addition, identify adjacent areas across the walls from use and storage locations and show that adequate steps have been taken to assure that radiation levels in unrestricted areas will not result in doses to individual members of the public in excess of those specified in 10 CFR 20.1301.

7. Please provide a description of the radiation monitoring instruments (e.g. gamma counter, solid state detector, portable or stationary count rate meter, portable or stationary dose rate or exposure rate meter, single or multi-channel analyzer, liquid scintillation counter, proportional counter, etc.) that will be used to perform radiation level detection, measurement, and contamination surveys.
8. Please confirm that the authorized users and radiation safety staff at the new location of use (formerly Omega Nuclear Diagnostics) have been trained and will follow the radiation safety program established under the Delaware Imaging Network license.

If you have any question, please feel free to call me at 610-337-5272 or better yet by e-mail.

Tara Weidner

Senior Health Physicist

US Nuclear Regulatory Commission